Ads
related to: prostate cancer on ultrasound procedure- Find an Imaging Site
Locate the nearest imaging site
or contact customer service.
- Case Studies
Review real case studies
with real patients.
- Sign Up for Updates
Sign up to receive the latest data,
case studies, and resources.
- Contact Us
Contact our representatives
for product and reimbursement info.
- Find an Imaging Site
Search results
Results From The WOW.Com Content Network
Transrectal ultrasonography, or TRUS in short, is a method of creating an image of organs in the pelvis, most commonly used to perform an ultrasound-guided needle biopsy evaluation of the prostate gland in men with elevated prostate-specific antigen or prostatic nodules on digital rectal exam.
Transrectal biopsy is a biopsy procedure in which a sample of tissue is removed from the prostate using a thin needle that is inserted through the rectum and into the prostate. [1] Transrectal ultrasound (TRUS) is usually used to guide the needle. [2] [3] The sample is examined under a microscope to see if it contains cancer.
Treatment for prostate cancer may involve active surveillance, surgery, radiation therapy – including brachytherapy (prostate brachytherapy) and external-beam radiation therapy, proton therapy, high-intensity focused ultrasound (HIFU), cryosurgery, hormonal therapy, chemotherapy, or some combination. Treatments also extend to survivorship ...
Prostate biopsy is a procedure in which small hollow needle-core samples are removed from a man's prostate gland to be examined for the presence of prostate cancer. It is typically performed when the result from a PSA blood test is high. [1] It may also be considered advisable after a digital rectal exam (DRE) finds possible abnormality.
In this procedure, a doctor inserts an ultrasound probe into the rectum, enabling them to see the prostate gland. Next, they insert a long, narrow tube called a cystoscope into the bladder.
Studies on localized prostate cancer showed that, after treatment, progression-free survival rates were high for low- and intermediate- risk patients with recurrent prostate cancer. [3] The InsighTec ExAblate 2000 was the first MRgFUS system to obtain FDA market approval, [4] US patent 5,247,935.
Ads
related to: prostate cancer on ultrasound procedure